Ege Üniversitesi Hastanesi veri tabanında kayıtlı erişkin Hodgkin lenfoma olgularının epidemiyolojik ve genel sağ kalım özelliklerinin retrospektif olarak değerlendirilmesi
Küçük Resim Yok
Tarih
2020
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Hodgkin lenfoma (HL) sıklığı ve mortalite oranları tüm dünyada değişkenlik göstermektedir. Bu çalışmada, HL olgularının epidemiyolojik ve genel sağ kalım analizlerinin, global sonuçlarla karşılaştırılarak değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi veri tabanına kayıtlı, 1992-2017 yıllarında HL tanısı alan 972 erişkin olgu retrospektif olarak değerlendirilmiş, CANREG-4 ile kaydedilen veriler SPSS’e aktarılmıştır. Bulgular: Olguların %59,9’u erkek olup, ortalama tanı yaşı 41,8 ve medyan tanı yaşı 39 idi. Olguların %94,4’ü klasik Hodgkin lenfoma (KHL) tanısı aldı. Alt tiplerine baktığımızda %42,1 nodüler sklerozan (NS)-KHL, %31,0 mikst sellüler (MS)-KHL, %5,2 lenfositten zengin (LZ)-KHL, %2,9 lenfositten fakir (LF)-KHL olarak değerlendirildi. Erkeklerde kadınlara göre anlamlı yüksekti. Noduler lenfosit predominant HL olgularının tamamı EBV negatif iken; KHL olgularının %52,7’si pozitifti (p<0,0001). Ayrıca %59 lokalize, %16,4 bölgesel, %24,7 yaygın hastalık oluşturmaktaydı. Sağ kalım analizleri bilinen 971 olgunun sağkalımı 1 yıllık %92, 5 yılllık %81, 10 yıllık %70, 15 yıllık %62, 25 yıllık %43 idi. Kemik iliği lokalizasyonundan tanı alan olguların sağ kalımının kısa olduğu saptandı (p<0,0001). Sonuç: HL, en sık görülen ikinci lenfoma tipi olup, erkeklerde kadınlara göre daha sık karşımıza çıkmaktadır. NSKHL en sık görülen alt tip olmakla birlikte, gelişmiş ülkelere göre biraz daha az görüldüğü, MSKHL ve LFKHL alt tiplerinin ise daha ön plana çıktığı dikkatimizi çekmektedir. Ayrıca olgularımızda EBV görülme oranları, gelişmiş ülkelere kıyaslandığında fazla olup, Asya ve Latin Amerika’ya göre daha düşüktür. Erkeklerde, kemik iliği tutulumu olanlarda ve yaygın hastalık oluşturanlarda sağ kalım daha kısa bulunmuştur. Prognostik açıdan, cinsiyet ve hastalık evresi bizim çalışmamızda da öne çıkan önemli parametreler arasında saptanmıştır.
Aim: Hodgkin lymphoma (HL) shows different incidence and mortality rates all over the world. The aim of this study was to evaluate the epidemiological and overall survival analysis of HL patients and compare them with global findings. Materials and Methods: The data of HL, including 972 adult patients diagnosed within 1992-2017 and recorded at Ege University Cancer Control and Research Center by CANREG-4 program, were evaluated retrospectively with SPSS. Results: 59.9% of the patients were male; the mean age was 41.8, and the median age was 39. Of all the patients, 94.4% were diagnosed as CHL. The subtypes of CHL were evaluated as 42.1% nodular sclerosis (NS)-CHL, 31.0% mixed cellular (MC)-CHL, 5.2% lymphocyte-rich (LR)-CHL, 2.9% lymphocyte-depleted (LD)-CHL. The disease was significantly predominant in males. While EBV was negative in all nodular lymphocyte predominant Hodgkin lymphoma patients, 52.7% of CHL patients were positive with EBV (p<0.0001). Also, 59% of the patients had localized, 16.4% regional, 24.7% disseminated disease. Overall survival rates for 1, 5, 10, 15, 25-year were 92%, 81%, 70%, 62%, 43% respectively. The patients those had been diagnosed with the bone marrow biopsy had been detected to have poor prognosis (p<0.0001). Conclusion: In our study, HL is the second most common lymphoma type; the incidence is more common in males than females. Although among our patients NSCHL is the most common subtype of CHL, it has a bit less percentage than developed countries, MCCHL and LDCHL subtypes are also prominent in our country. Also, our EBV incidence is higher compared with developed countries but lower than in Asia and Latin America. Overall survival is found lower in patients with male gender, bone marrow involvement, and disseminated disease. Gender and stage of the disease were found to be among the most important prognostic parameters in our study.
Aim: Hodgkin lymphoma (HL) shows different incidence and mortality rates all over the world. The aim of this study was to evaluate the epidemiological and overall survival analysis of HL patients and compare them with global findings. Materials and Methods: The data of HL, including 972 adult patients diagnosed within 1992-2017 and recorded at Ege University Cancer Control and Research Center by CANREG-4 program, were evaluated retrospectively with SPSS. Results: 59.9% of the patients were male; the mean age was 41.8, and the median age was 39. Of all the patients, 94.4% were diagnosed as CHL. The subtypes of CHL were evaluated as 42.1% nodular sclerosis (NS)-CHL, 31.0% mixed cellular (MC)-CHL, 5.2% lymphocyte-rich (LR)-CHL, 2.9% lymphocyte-depleted (LD)-CHL. The disease was significantly predominant in males. While EBV was negative in all nodular lymphocyte predominant Hodgkin lymphoma patients, 52.7% of CHL patients were positive with EBV (p<0.0001). Also, 59% of the patients had localized, 16.4% regional, 24.7% disseminated disease. Overall survival rates for 1, 5, 10, 15, 25-year were 92%, 81%, 70%, 62%, 43% respectively. The patients those had been diagnosed with the bone marrow biopsy had been detected to have poor prognosis (p<0.0001). Conclusion: In our study, HL is the second most common lymphoma type; the incidence is more common in males than females. Although among our patients NSCHL is the most common subtype of CHL, it has a bit less percentage than developed countries, MCCHL and LDCHL subtypes are also prominent in our country. Also, our EBV incidence is higher compared with developed countries but lower than in Asia and Latin America. Overall survival is found lower in patients with male gender, bone marrow involvement, and disseminated disease. Gender and stage of the disease were found to be among the most important prognostic parameters in our study.
Açıklama
Anahtar Kelimeler
[No Keywords]
Kaynak
Ege Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
59
Sayı
supplement
